Related articles
-
Article
Valeant’s financial restatement begs compliance questions
Valeant Pharmaceuticals’ announced financial restatement raises questions about the drug company’s compliance program and its business model. But it might also serve as an early warning to all publicly listed U.S. companies about the increased room for misjudging the booking of sales once FASB rolls out its new revenue recognition ...
-
ArticleU.K. hopes to create ‘third way’ in AI regulation between EU and U.S.
The U.K.’s data regulator has unveiled a new enforcement approach to AI development and usage that experts say seeks to carve a middle way between the strict rules applied by the European Union (EU) and the pro-industry, light-touch regime favored by the U.S.
-
WebcastAug 7 | No Longer Optional: The Future of AI in TPRM
Don’t miss this opportunity to prepare your organization for the future of TPRM and stay ahead with AI as your second-in-command.